GENERAL COMMENTS
This paper describes the design and protocol for a clinical trial which will test whether a text message program can improve cardiovascular disease outcomes and medication adherence.
There is a good rationale for the trial, and the eligibility criteria has been designed to improve its external validity and generalizability in the LMIC where it will be conducted (Columbia). The trial design affords many strengths, particularly for a trial testing an mHealth approach -and these include the use of biomarkers for endpoints, a large sample size with appropriate statistical power, and longterm follow-up (12 months primary outcome and follow-up through 36 months). The randomization process is centralized and staff will be blinded to participant arm assignment when conducting assessments. The research team has carefully developed the text messages through a systematic process of gathering end-user input and feedback, and the text messages helpfully include a variety of content and are sent on a time-varying schedule (from high frequency to low over a period of months), another strength.
The manuscript describing the trial addresses critical and necessary aspects of trial design and protocol reporting. As an ongoing trial, it appropriately notes the trial start date for the trial, does not report any results or conclusions of the trial, and indicates that the trial has been registered at clinicaltrials.gov.
Since the study has been active and enrolling for some time, this reviewer is chiefly limiting comments to aspects of the trial that could be better delineated in the paper.
1) On the text messages: a. When the intervention text messages were developed through formative research, was there any patient input on the frequency or timing of the text messages, beyond their content? The authors could also better describe the rationale for sending the text messages on a decreasing frequency over time, since that is one strength of the work. b. The text messages have been informed by the Transtheoretical Model. However, the trial neither assesses where participants currently stand on the Transtheoretical Model Stages of Change, nor targets the messages accordingly. Although this makes the text message program more practical, it also loses the advantage and potential impact of delivering individually-tailored messages. The authors should further clarify how the text messages relate to the Transtheoretical Model and its Stages of Change, and whether/how the sequencing of the text message content corresponds to those stages. c. Are the intervention text messages strictly one-way, or do any of them allow for bidirectional communication, i.e., being able to text or call a nurse with any questions?
2) The clarity and language describing the comparison arm could be improved. a. It seems that comparison arm participants are only receiving messages that thank them for their trial participation and remind them of trial appointments. Please further clarify this in the "choice of comparator" section, page 10 lines 3-15 -and specify the frequency of text message receipt in the comparison arm (elsewhere it says monthly?) b. The comparison arm is described as a "placebo group" --is this the best language to describe the comparison arm? How does the number and frequency of the text messages in the comparison arm compare to intervention arm?
3) The trial includes a lengthy follow-up with a primary outcome at 12 months and follow-up as long as 36 months. What methods are used to help retain participants and reduce loss-to-follow-up over the long duration of this trial?
4) The MARS-5 rating scale for adherence has some validation data behind it. A few questions: a. In this trial, do participants use a time interval (e.g. last 30 days) when characterizing their adherence on the MARS-5? b. Is the measure self-administered or administered by an interviewer to the participant? c. MARS-5 does not assess the number of pills taken vs. the number prescribed. Is there any other questionnaire in the study that directly quantifies medication taking behavior? Why or why not?
5) The aim and objective of the study (page 9, lines 41-47) should include mention of the primary outcomes of the study. In particular, it was powered on reductions in LDL-C. (page 14, lines 5-6).
6) This paper would benefit from careful proofreading. a. There is some errant text inside the paper (e.g., page 16, lines 3-13; page 16, list 24-25) which may be commentary from a prior review or team member? b. The English grammar could be strengthened in a few places (e.g., page 3 line 48-49 and 60; page 5 line 49-50; page 8 line 5; page 10 lines 4-7).
REVIEWER

Richard Katz
George Washington University USA REVIEW RETURNED 31-Mar-2019 GENERAL COMMENTS SMS messaging using behavioral change techniques to support medication adherence in patients with CAD is a worthy approach. This study design, however, appears to have several limitations that may only partially improve patient medication adherence and not clearly impact the primary outcomes. In general there can be 2 types of mHealth medication adherence messages-1) daily reminders to take meds and 2) behavioral support messages. This study limits it's approach only to the latter rather than both. The research team has designed and tested their behavioral messaging which is a strength, but, it is hard to assess if repeating the messages will cause message fatigue and if once a week messaging for the majority of time is sufficient without daily medication alerts. Ability to assess the primary endpoints seems limited. It is unclear if 1) many patients will already be on medications at onset of the study, 2) how many patients may already be very adherent at baseline with no room for improvement over time, and 3) how to handle medication dose adjustments over the course of the study. Assessment of lipid medication adherence is the strongest endpoint, though ther are the concerns listed above. Checking one baseline and one followup lipid profile is a good measure of recent medication adherence. In contrast, single blood pressure measurements (baseline and followup) are inadequate to assess medication adherence. Blood pressure evaluation requires a "trend analysis" of several measures to know medication effect. Understanding antihypertensive medication adherence is further complicated by the need for multiple blood pressure meds and the need to take pills twice or even three times a day. Assessing heart rate response to beta blockers also can be challenging depending on the specific beta blocker and timing of dosing (different half-life, once a day versus twice a day). The other problem with blood pressure and beta blocker meds in research studies is that the patient may have intermittent adherence on most weeks, but decide to take their medications (and please the study team) when there is a study visit scheduled, thus not reflecting their overall adherence. Another factor in medication adherence may be patients who get 30 day versus 90 day prescriptions with refills.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1
Reviewer Name: Aravinda Thiagalingam Institution and Country: Westmead Hospital, Sydney Australia 1. I am surprised that a pill count or some other direct measure of adherence is not being performed as a secondary outcome (if only in a subgroup). Answer: To assess adherence we use biomarkers and the MARS scale. We will not use a pill count because we wanted to have a pragmatic trial as close as real treatment management as possible where people do not normally do pill counts.
Overall, we agree with the reviewer that there are potential limitations to every measure of adherence, including self-report (as suggested by reviewer 1), and electronic medication packaging devices (which are too expensive for the available resource), and biological measures. We have followed the advice in Lam & Fresco's overview of medical adherence measures ) by using a combination of measures, which have clinical relevance, and are unlikely to have excessive impact on the behavior under study. We have selected change in LDL as the primary outcome as the biological measure most sensitive to medication 2. The control group will still get a large number of messages (monthly). May this affect the outcome?
Answer: Designing an appropriate comparator is always a challenge in trials of digital health interventions. We have designed these control messages to have minimal impact on behavior, so they only contain content expressing gratitude for participation in the study and for completing follow up measures. This has been clarified in the section on choice of comparator (p6). Additionally, we need to remember that our hypothesis is that the intervention is based on behaviour change techniques not just simple reminders.
Reviewer 2 Reviewer Name: Michael Stirratt Institution and Country: National Institute of Mental Health, United States of America
We would like to thank you for your comments and observations. We are sure that your evaluation improved the quality of our work.
1) On the text messages:
a. When the intervention text messages were developed through formative research, was there any patient input on the frequency or timing of the text messages, beyond their content? The authors could also better describe the rationale for sending the text messages on a decreasing frequency over time, since that is one strength of the work. Answer: In the focus groups, we asked patient's about frequency and timing for delivering messages; they answered they would prefer reading messages in the day at working hours, between 8: 00. a.m. to 6:00 p.m. This has been clarified in the section on the intervention and its development (page 7). The Transtheoretical model states that patients go through different stages to achieve change. In the early stages, they require more intensive follow-up, since the behaviors are in a learning phase. Subsequently, in the maintenance stages, the model suggests that less reinforcement is required. This has been clarified in the section on the intervention and its development (page 7). Finally, we are preparing a paper with a detailed description of SMS development that will be published separately.
b. The text messages have been informed by the Transtheoretical Model. However, the trial neither assesses where participants currently stand on the Transtheoretical Model Stages of Change, nor targets the messages accordingly. Although this makes the text message program more practical, it also loses the advantage and potential impact of delivering individually-tailored messages. The authors should further clarify how the text messages relate to the Transtheoretical Model and its Stages of Change, and whether/how the sequencing of the text message content corresponds to those stages. Answer: The text messages were designed to supply each of the stages of the model. During the writing design, an amount corresponding to the needs of the stage was assigned, including content, frequency and quantity. We obtained this information from the focus groups, through which the needs of the patients were identified. These needs were classified according to the model. Within the design we contemplate the convenience of evaluating the status of patients in relation to the model. Also, we considered the advantage that the messages were personalized. However, because this is a pragmatic trial, we decided to design identical messages for all patients. In our countries the health system does not have the capacity to carry out an individualized follow-up of patients; in this sense, we want to offer patients tools that will help them to act in their real context. Otherwise, in our context, we do not have digital clinical records which are needed to generate the algorithms to assign messages according to the different characteristics of the patients. The financial reasons for not personalizing messages have been added to the section on page 7 describing the intervention.
c. Are the intervention text messages strictly one-way, or do any of them allow for bidirectional communication, i.e., being able to text or call a nurse with any questions? Answer: The design is contemplated in only one direction. Messages send by patients will not be answered. During the first interview, we will explain to the participants that they should not answer the messages, and that if they have doubts or concerns in relation to the research, they can call the study coordinator. We will share this contact number with patients in this first interview as well. Patients will be able to share with the coordinator through phone call the following information: change or lose of cell phone number, change of residency address, new adverse events or if they are not receiving text messages appropriately. Participants will not be able to share information related with their health care insurance (appointments, medications, exams, etc.). During the first interview, we will indicate participants in which cases they can communicate with the coordinator by phone call, and we will clarify that we will not be able to answer questions related with their health care services. This has been clarified on page 7.
2) The clarity and language describing the comparison arm could be improved.
a. It seems that comparison arm participants are only receiving messages that thank them for their trial participation and remind them of trial appointments. Please further clarify this in the "choice of comparator" section, page 10 lines 3-15 -and specify the frequency of text message receipt in the comparison arm (elsewhere it says monthly?) Answer: we clarify in the section "comparator choice" the frequency of control messages.
b. The comparison arm is described as a "placebo group" --is this the best language to describe the comparison arm? How does the number and frequency of the text messages in the comparison arm compare to intervention arm? Answer: We changed in the document "placebo" by "control group". We will send to control group one message per month with neutral content (gratefulness and follow up). Intervention group will receive neutral messages as well once per month. This has been clarified in the sections on choice of comparator and description of the intervention.
3) The trial includes a lengthy follow-up with a primary outcome at 12 months and follow-up as long as 36 months. What methods are used to help retain participants and reduce loss-to-follow-up over the long duration of this trial? Answer: Our design aims to minimize reactivity of assessment and the Hawthorne effect while maximizing retention to follow up. The following strategies to prevent loss-to follow-up will be used: 1) One phone call at the third month of participation. Trained personnel different from the other interviewers will phone the participants, this, to guarantee the blind design. Professionals in charge of the follow-up are trained in patient's contact; with ability to empathize with volunteers. 2) We will register at least three relative number contact, so that, in the case we will not be able to reach the patient, we will phone the participant's relatives. 3) We will register the address participants, so that, in the case we will not reach the patients nor the relatives, we will arrange a domiciliary visit. 4) We will share with the participants a contact phone number, in order to they let us to know if they change their phone number contact. We will explain these strategies to participants, in order to get permission for further contact. This has been added to page 13. 4) The MARS-5 rating scale for adherence has some validation data behind it. A few questions:
a. In this trial, do participants use a time interval (e.g. last 30 days) when characterizing their adherence on the MARS-5? Answer: Patients will be recruited after they complete at least 30 days of treatment after discharge, this, in the case of their first cardiovascular event. Patients who have several events may participate at any time of their last discharge, since they are on medication treatment. We will ask adherence in the last seven days. Moreover, MARS 5 has one question regarding the percentage of medication patients have taken in the last month (30 days).. b. Is the measure self-administered or administered by an interviewer to the participant? A trained psychologist will administer the MARS 5. The questionnaire will be applied in person with the patient c. MARS-5 does not assess the number of pills taken vs. the number prescribed. Is there any other questionnaire in the study that directly quantifies medication taking behavior? Why or why not? Answer: We only will used MARS 5 as a standardized questionnaire. But in our extended interview format, we will ask the number of pills they take and the number of pills their physician has prescribed.
5) The aim and objective of the study (page 9, lines 41-47) should include mention of the primary outcomes of the study. In particular, it was powered on reductions in LDL-C. (page 14, lines 5-6). Answer: We included the LDL-C reductions in the aim study.
Reviewer 3
Reviewer Name: Richard Katz Institution and Country: George Washington University, USA We would like to thank you for your comments and observations. We are sure that your evaluation improved the quality of our work. 1). SMS messaging using behavioral change techniques to support medication adherence in patients with CAD is a worthy approach. This study design, however, appears to have several limitations that may only partially improve patient medication adherence and not clearly impact the primary outcomes. In general, there can be 2 types of mHealth medication adherence messages-1) daily reminders to take meds and 2) behavioral support messages. This study limits its approach only to the latter rather than both. The research team has designed and tested their behavioral messaging, which is a strength, but it is hard to assess if repeating the messages will cause message fatigue and if once a week messaging for the majority of time is sufficient without daily medication alerts. Ability to assess the primary endpoints seems limited. Answer: As the reviewer indicates, is indeed uncertainty, the effectiveness of the intervention based on RCTs for adherence in these patients, nevertheless, this is the question we would like to answer in our study. Despite of, we are aware that fatigue in this kind of intervention is hard to evaluate. However, we need to point out that studies have suggested that recorded messages are more likely to cause fatigue . Our intervention is based on Transtheoretical Change Model and we did not include recorded type messages. We did include messages related with categories corresponding to this model, in order to prevent volunteers' fatigue. None of the messages will be repeated since we have created enough messages to fulfill the complete intervention. Besides, we plan that the last ten months of intervention, participants will receive one messages per week, but randomly; patients will not get one message every Sunday or Wednesday; the will not be able to know when they will the message. We hope this contribute to prevent fatigue as well.
On another hand, according to Sabin et al one-way messages have proven being an efficient intervention. We are aware that bidirectional messages haven proven to be more efficient that oneway type, however we had to consider other variables from our context; first we can not afford the economical cost of this kind of intervention; likewise, the technology and personnel needed are beyond our capacities and possibilities. Besides, we evaluate the health system conditions of our country and other low-in-come countries in which the access to health care is limited. We considered that bidirectional messages strategy could lead to a dependence of patients to the research professionals; because, as they do not have an efficient communication with health team, they could ask us about their insurance and other diligences they need to do in order to get health service. We wanted to emulate as well as possible real conditions to patient's context and not provide a temporal help that minimize the participant's ability to cope with the system's issues.
2) It is unclear if a. many patients will already be on medications at onset of the study, Answer: We will only recruit patients who are in a medication treatment. The minimum time that patients should have in outpatient treatment should be at least one month. This has been clarified in the eligibility criteria (page 6) b. how many patients may already be very adherent at baseline with no room for improvement over time, Answer: Our design is a randomized clinical trial. The randomization guarantees that both groups include patients with different levels of adherence. Moreover, as we will record longitudinal data, we will be able to identify if patients who had a good initial adherence level could maintain it. Besides, the Transtheoretical Change Model contemplates a maintenance stage.
c. how to handle medication dose adjustments over the course of the study. Answer: First, we need to clarify that our study does not pretend to evaluate the medication effect, rather the increasing of adherence. And, second, because our design is a randomized clinical trial, we can guarantee that patients with different doses and different doses adjustment conform both groups comparably.
3). Checking one baseline and one follow up lipid profile is a good measure of recent medication adherence. In contrast, single blood pressure measurements (baseline and follow up) are inadequate to assess medication adherence. Answer: Overall, we agree with the reviewer that there are potential limitations to every measure of adherence, including self-report (as suggested by reviewer 1), and electronic medication packaging devices (which are too expensive for the available resource), and biological measures. We have followed the advice in Lam & Fresco's overview of medical adherence measures ) by using a combination of measures, which have clinical relevance, and are unlikely to have excessive impact on the behavior under study. We have selected change in LDL as the primary outcome as the biological measure most sensitive to medication. 4). Blood pressure evaluation requires a "trend analysis" of several measures to know medication effect. Understanding antihypertensive medication adherence is further complicated by the need for multiple blood pressure meds and the need to take pills twice or even three times a day. Answer: First, we need to clarify that our study does not pretend to evaluate the medication effect, rather the increasing of adherence. And, second, because our design is a randomized clinical trial, we expect both groups to have comparable numbers of patients with different doses and different doses adjustment. Thirdly, this is a secondary outcome. 5). Assessing heart rate response to beta blockers also can be challenging depending on the specific beta blocker and timing of dosing (different half-life, once a day versus twice a day). Answer: We are aware of these measure limitations, that is why, we will evaluate the difference between groups, but we will not evaluate the therapeutic effect of beta blockers. We found in the literature that heart rate is a significant variable and for that reason, we decided to consider the variables as a secondary outcome in our trial. 6). The other problem with blood pressure and beta blocker meds in research studies is that the patient may have intermittent adherence on most weeks but decide to take their medications (and please the study team) when there is a study visit scheduled, thus not reflecting their overall adherence. Answer: We are aware of limitations related with measuring intermittent adherence. Adams et al found that patients should receive stable doses during three to twelve weeks before the evaluation. No trial is perfect, but we believe that the combination of secondary outcome measures, combined with the change in lipids as the primary outcome, will be as robust as is possible in the context of a pragmatic trial in an LMIC. 7). Another factor in medication adherence may be patients who get 30 day versus 90-day prescriptions with refills. Answer: Because our the randomized assignment in our design, we expect a similar distribution of this variable in both arms, so it should not be a confounder.
VERSION 2 -REVIEW
REVIEWER
Aravinda Thiagalingam
Westmead Hospital, Australia REVIEW RETURNED 27-May-2019 trained engineer will be monitoring the patient's answers. We have clarified this by adding this information to the "intervention" section (page 7, lines 32-37 and page 8 lines 1 and 2).
2. Will any information on the class of drugs prescribed to the patient be sought? Will this be used to tailor the messages?
Answer: We will ask about the class of medications, however we will not use tailored messages, this is now explained in the "intervention" section.
3. It would be useful to have some examples of messages that will be sent.
Answer: Thanks for this useful suggestion; we have added a reference with the preprint article in which we described the text message intervention design. This article includes some examples of the messages we will use in the intervention (page 7 line 23).
4. Do the authors have information regarding the current adherence rates of these medications in their proposed patient group?
Answer: We took as reference the PURE study since our trial is not only designed for Colombia but to other countries with similar health care access conditions. We explained this in the introduction and have cited this study (page 3 line 37).
Reviewer 3
Reviewer Name: Richard Katz Institution and Country: George Washington University, USA 1). The major concern regarding this study design is that LDL reduction is the primary endpoint of this study. Since all subjects will be on statins at entry, many, if not most, subjects may already be adherent at baseline, especially since all will be receiving secondary prevention with higher chance of motivation. Also, by already being on a statin there is less likelihood they might have further statin dose changes during the study period. Therefore adherence (by keeping on their daily doses) may better reflected by no increase of LDL during the study period. This adherence could be verified by checking prescription refill history through subject's pharmacy or insurance records. As noted by the author's comments, both heart rate and blood pressure will be weak secondary endpoints since neither can be reliably assessed by only a few measurements.
Though frequent reminders to take medications may not be necessary, it still would be helpful for subjects to get timely reminders to refill prescriptions, especially those on 30 day refill programs.
Answer: This is a clinical trial in which we will compare difference between differences (what is the difference endline-baseline in intervention versus comparison) so the main effect we are looking is between arms.
Regarding other measures of adherence we can acknowledge this is always challenging but we are triangulating different data (self-reported plus biomarkers) we can say that although secondary analysis of insurance or pharmacy could be potentially useful it also has limitations and it was not feasible in our setting but we can acknowledge as a general limitation (as in all the studies of adherence).
Regarding LDL, we have followed the advice in Lam & Fresco's overview of medical adherence measures by using a combination of measures, which have clinical relevance, and are unlikely to have excessive impact on the behavior under study. We have selected change in LDL as the primary outcome as the biological measure most sensitive to medication.
Finally, our trial is pragmatic, which means we intend to emulate as well as possible the actual conditions of the health care system of our population. Health care system in countries like Colombia do not include reminders to refill prescriptions, that is why patients have to learn to be independent and autonomous. Besides, as we stated, we designed an intervention based on change behavior which aims to promote healthy permanent habits that do not depend on external help.
Editorial requests 1) Please ensure that all comments raised by reviewer 2 in the previous round of review are addressed within the manuscript text. For example, point 4 was addressed in your response to the reviewers but not with changes to the manuscript. Please make the appropriate revisions to the text.
Answer: We added information in the section "self-reported adherence" regarding MARS-5 comments. We have already addressed the rest of the comments.
2) On page 15, please change "Indirect Patient and Public Involvement" to "Patient and Public Involvement"
Answer: we changed this sentence as requested.
VERSION 3 -REVIEW
REVIEWER
Richard Katz George Washington University School of Medicine United States REVIEW RETURNED
07-Aug-2019
GENERAL COMMENTS
It is hard to make major revisions on the study design/analysis after the fact of completing the study. It might be helpful to expand on the limitations section incorporating the challenges: 1) Since most patients will start the study already on statins, the LDL changes are hard to judge. It appears that the power calculation is based on pre versus post statin treatment, rather than on-therapy at baseline changes; 2) There is no power calculation for heart rate and blood pressure change and both endpoints are "soft" due to the limits of comparing entry and exit measures. These might be better considered secondary endpoints; 3) Unknown adherence at baseline may have limited the impact of the intervention; 4) There may be better approaches to validating adherence such as pharmacy records compared to "self-report.".
